In this issue:
JAK inhibitor selection in challenging scenarios of myelofibrosis
Genomic profiling for decisionmaking in secondary myelofibrosis
Baseline and new/worsening anaemia during ruxolitinib linked to poorer survival
Statins may improve cardiovascular outcomes in patients with PV/ET
Life expectancy curtailed in all MPNs but worst in myelofibrosis
REFINE: Navitoclax plus ruxolitinib for patients ineligible for transplant
CD38+ monocytes drive fibrotic progression
The role and impact of non-driver gene mutations in myelofibrosis
Please login below to download this issue (PDF)